The Protocol-Specific Research Support (PSRS) is an effort to expand the number of investigator-initiated clinical trials at KCI. Support must be available to conduct preliminary studies, most of which are not presently funded by the NCI or other agencies. The purpose of the PSRS is to provide an administrative support mechanism to provide data management, collection of patient data, and to support innovative clinical trials within the Cancer Center. The objective is to foster investigator-initiated trials, which bring new results from our basic science laboratories to the clinical and population studies arenas. The awarding of PSRS to an investigator is done at the recommendation of the Scientific Leadersip Council. Associate center directors, Program leaders, or heads of the Multidisciplinary Teams can nominate protocols for support. Proposals are evaluated for their scientific merit and importance in developing new avenues of research within the Cancer Center. Although all proposals are given serious consideration, studies that show the potential to develop new avenues of research and secure external funding are encouraged. There are many investigator-initiated translational studies within the Cancer Center. These include novel and molecular targeted therapies, and functioning imaging techniques. These trials seek to test new, targeted therapies both as single agents, and in combination with more established cytotoxic therapy. They often include measurements of treatment effect based on blood samples and tumor biopsies. New imaging approaches are integral to this work as they provide a noninvasive way to test these treatment approaches. For the future, we plan to support a mixture of Phase I, Phase II, and imaging/correlative trials. Funding support for 1.5 FTE data management to support the innovative trials is requested. Data management will include confirming patient eligibility prior to registration to the trial, abstracting and collating data from various sources ensuring that qualtiy control checks are being conducted.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA022453-26
Application #
7324153
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2006-12-01
Budget End
2007-11-30
Support Year
26
Fiscal Year
2007
Total Cost
$95,196
Indirect Cost
Name
Wayne State University
Department
Type
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Herroon, Mackenzie K; Rajagurubandara, Erandi; Diedrich, Jonathan D et al. (2018) Adipocyte-activated oxidative and ER stress pathways promote tumor survival in bone via upregulation of Heme Oxygenase 1 and Survivin. Sci Rep 8:40
Colacino, Justin A; Azizi, Ebrahim; Brooks, Michael D et al. (2018) Heterogeneity of Human Breast Stem and Progenitor Cells as Revealed by Transcriptional Profiling. Stem Cell Reports 10:1596-1609
Blocker, Stephanie J; Shields, Anthony F (2018) Imaging of Nanoparticle Distribution to Assess Treatments That Alter Delivery. Mol Imaging Biol 20:340-351
Guastella, Anthony R; Michelhaugh, Sharon K; Klinger, Neil V et al. (2018) Investigation of the aryl hydrocarbon receptor and the intrinsic tumoral component of the kynurenine pathway of tryptophan metabolism in primary brain tumors. J Neurooncol 139:239-249
Li, Feng; Wang, Yongli; Li, Dapeng et al. (2018) Perspectives on the recent developments with green tea polyphenols in drug discovery. Expert Opin Drug Discov 13:643-660
Ramseyer, Vanesa D; Kimler, Victoria A; Granneman, James G (2018) Vacuolar protein sorting 13C is a novel lipid droplet protein that inhibits lipolysis in brown adipocytes. Mol Metab 7:57-70
Healy, Mark A; Morris, Arden M; Abrahamse, Paul et al. (2018) The accuracy of chemotherapy ascertainment among colorectal cancer patients in the surveillance, epidemiology, and end results registry program. BMC Cancer 18:481
Lacher, Sarah E; Alazizi, Adnan; Wang, Xuting et al. (2018) A hypermorphic antioxidant response element is associated with increased MS4A6A expression and Alzheimer's disease. Redox Biol 14:686-693
Alsaab, Hashem O; Sau, Samaresh; Alzhrani, Rami M et al. (2018) Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages. Biomaterials 183:280-294
Chammaa, May; Malysa, Agnes; Redondo, Carlos et al. (2018) RUMI is a novel negative prognostic marker and therapeutic target in non-small-cell lung cancer. J Cell Physiol 233:9548-9562

Showing the most recent 10 out of 826 publications